Is intravenous glutathione indicated for non‑alcoholic fatty liver disease, and what is the recommended dosing regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Intravenous Glutathione is NOT Indicated for Non-Alcoholic Fatty Liver Disease

Intravenous glutathione should not be used for the treatment of non-alcoholic fatty liver disease (NAFLD), as there is no FDA-approved indication for this use, no established dosing regimen, and no high-quality evidence demonstrating benefit on clinically meaningful outcomes such as mortality, progression to cirrhosis, or quality of life.

Critical Evidence Against Use

FDA Drug Label Explicitly Prohibits This Use

The only FDA-approved glutathione IV formulation (BSS PLUS®) is specifically labeled for intraocular irrigation during ophthalmic surgery only 1. The drug label explicitly states: "NOT FOR INJECTION OR INTRAVENOUS INFUSION" and warns that it is "for reconstitution of irrigation solution only" 1. This represents a fundamental contraindication to systemic IV administration for any indication, including NAFLD.

Absence from Evidence-Based Guidelines

The 2022 BASL/BSG consensus guidelines for NAFLD management—the most recent and comprehensive quality standards for NAFLD care—make no mention of glutathione therapy in their evidence-based recommendations 2. These guidelines underwent rigorous GRADE methodology evaluation and modified Delphi consensus process with ≥80% agreement thresholds. The complete absence of glutathione from these authoritative recommendations is telling.

Limited and Low-Quality Supporting Evidence

Outdated and Methodologically Weak Studies

The only clinical evidence suggesting potential benefit comes from:

  • A 1995 Italian study showing improvements in liver enzymes (bilirubin, AST, ALT, GGT) with 1800 mg/day IV glutathione in chronic steatotic liver disease 3. However, this study is nearly 30 years old, predates modern NAFLD diagnostic criteria, and lacks data on hard outcomes like fibrosis progression, cirrhosis, or mortality.

  • A 2025 literature review examining only 3 small studies (total n=109 participants) that showed improvements in ALT and oxidative stress markers like 8-OHdG 4. The authors themselves acknowledge "small sample sizes and inconsistent protocols limit generalizability" and emphasize that "further large-scale RCTs are required to confirm GSH's efficacy" 4.

No Evidence for Mortality or Disease Progression Benefit

None of the available studies demonstrate that IV glutathione reduces:

  • Liver-related mortality
  • Progression to cirrhosis
  • Development of hepatocellular carcinoma
  • Need for liver transplantation
  • Overall quality of life improvements

These are the outcomes that matter clinically, yet they remain completely unstudied.

Mechanistic Rationale Does Not Equal Clinical Efficacy

While oxidative stress plays a pathophysiological role in NAFLD progression 5, 6, and fatty livers show reduced glutathione levels 7, mechanistic plausibility does not substitute for clinical trial evidence. The leap from "oxidative stress is involved" to "IV antioxidant therapy improves outcomes" has failed repeatedly in medicine (e.g., vitamin E trials, beta-carotene in cancer prevention).

Common Pitfalls to Avoid

  • Do not confuse oral glutathione supplementation with IV administration—they have different pharmacokinetics and safety profiles
  • Do not extrapolate from acetaminophen toxicity studies 7—this is a completely different clinical scenario requiring N-acetylcysteine (a glutathione precursor), not glutathione itself
  • Do not use off-label IV glutathione preparations marketed by compounding pharmacies without FDA approval or quality control
  • Recognize that improving surrogate markers (like ALT or oxidative stress biomarkers) does not guarantee improvement in patient-centered outcomes

What Should Be Done Instead

For NAFLD management, focus on evidence-based interventions that actually reduce morbidity and mortality:

  • Weight loss of 7-10% through lifestyle modification (diet and exercise)
  • Management of metabolic comorbidities: diabetes control, dyslipidemia treatment, hypertension management
  • Consideration of pharmacotherapy with agents that have demonstrated efficacy in clinical trials (e.g., pioglitazone for biopsy-proven NASH, GLP-1 receptor agonists)
  • Cardiovascular risk reduction, as cardiovascular disease remains the leading cause of death in NAFLD patients 2

In the absence of FDA approval, guideline support, and high-quality evidence demonstrating benefit on hard clinical outcomes, IV glutathione cannot be recommended for NAFLD treatment in clinical practice.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.